NON-SMALL CELL LUNG CANCER STAGE III
Clinical trials for NON-SMALL CELL LUNG CANCER STAGE III explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER STAGE III trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER STAGE III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to stop lung cancer from returning
Disease control OngoingThis study tests whether adding the drug durvalumab to targeted radiation (SBRT) can help keep early-stage non-small cell lung cancer from coming back. It included 13 people with stage I to IIIA disease. The main goal was to see how long they lived without their cancer getting wo…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for stage III lung cancer: targeted pill may delay progression
Disease control OngoingThis phase 3 study tests whether the targeted drug osimertinib can keep stage III EGFR-mutant lung cancer from progressing after initial chemoradiation. About 216 participants will receive either osimertinib or a placebo daily until their cancer worsens or side effects become una…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Blood test may predict lung cancer outcomes before surgery
Knowledge-focused OngoingThis study is looking at 100 people with stage IIIA lung cancer who are getting treatment before surgery. Researchers want to see if a blood test that looks for tumor DNA (ctDNA) can predict how well patients do. If the tumor DNA disappears after treatment, it might mean a better…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Sponsor: Fundación GECP • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Your gut bugs may hold the key to lung cancer therapy
Knowledge-focused OngoingThis study looks at whether bacteria in the gut and throat can predict how well stage III lung cancer patients respond to the immunotherapy drug durvalumab after chemoradiation. Researchers will collect stool, throat swabs, and breath samples from 126 participants to see if these…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC